# US 7,407,759 B2 · Genetic alterations associated with prostate cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,407,759 B2
- Document ID: US7407759B2
- Status: Granted
- Kind: B2
- Application number: 11/267,616
- Filed: 2005-11-04
- Published: 2006-07-06
- Granted: 2008-08-05
- Earliest claimed: 1996-06-03
- Assignees: The Regents of the University of California
- Inventors: Ronald H. Jensen; Michael L. Cher
- Web page: https://patentgrep.com/patent/US7407759B2

## CPC

- C12Q 1/6841: In situ hybridisation
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides new probes for the detection of prostate cancer cells. The probes bind selectively with target polynucleotide sequences selected from the group consisting of 2q, 4q, 5q, 6q, 10p, 15q, 1q, 2p, 3q, 3p, 4q, 6p, 7p, 7q, 9q, 11p, 16p, and 17q.

## Claims

### Claim 1

A method for screening for the presence or absence of genetic alterations correlated with the presence of prostate cancer cells in a sample, the method comprising:
contacting a nucleic acid sample from an African American human patient with a probe which binds selectively to a target polynucleotide sequence on a genomic region in which copy number, from about 4q25 to about 4q28, is increased in prostate cells; and
wherein the probe is contacted with the sample under conditions in which the probe binds selectively with the target polynucleotide sequence to form a stable hybridization complex and detecting the formation of a hybridization complex; and;
detecting the presence or absence of a hybridization complex thereby screening for the presence or absence of a genetic alteration correlated with the presence of prostate cancer cells in the sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein the chromosome region in which copy number is increased is from about 4q27 to about 4q28.

### Claim 3 (depends on 1)

The method of claim 1, further comprising contacting the sample with a reference probe which binds selectively to a centromeric DNA.

### Claim 4 (depends on 1)

The method of claim 1, wherein the nucleic acid sample is from a prostate biopsy sample from the patient.

### Claim 5 (depends on 1)

The method of claim 1, wherein the step of detecting the hybridization complex comprises determining the copy number of the target sequence.

### Claim 6 (depends on 1)

The method of claim 1, wherein the probe is labeled with digoxigenin or biotin.

### Claim 7 (depends on 1)

The method of claim 1, wherein the step of detecting the hybridization complex is carried out by detecting a fluorescent label.

### Claim 8 (depends on 7)

The method of claim 7, wherein the fluorescent label is FITC.

### Claim 9 (depends on 1)

The method of claim 1, wherein the sample comprises a metaphase cell.